07.11.22
Headquarters: New Brunswick, NJ
twitter.com/JNJNews
www.jnj.com
Headcount: 141,700
Year Established: 1886
Pharma Revenues: $52,080 (+14%)
Net Income: $20,878 (+42%)
R&D: $14,714 (+21%)
TOP SELLING DRUGS
Johnson & Johnson (J&J) is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. The pharmaceutical segment is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Sales across these therapeutic areas were $52 billion in 2021, a 14.3% growth over the previous year.
During the year, J&J received FDA approval for two new products: Rybrevant (amivantamab-vmjw), the first targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations, and Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis.
In addition to these newly launched products, J&J received approvals for additional indications, new formulations and combination therapies, and continued to advance key pipeline programs such as its BCMA-directed CAR-T cell therapy program and entry into gene therapy with a focus on retinal diseases.
Infectious disease product sales jumped 64% to $5.9 billion in 2021, driven largely by J&J’s COVID-19 vaccine. This was partially offset by lower sales of Prezista and Prezcobix/Rezolsta due to increased competition and loss of exclusivity of Prezista in certain countries outside the U.S.
Neuroscience products recorded sales of $7 billion, an increase of 7.1%. Paliperidone long-acting injectables growth was driven by sales of the schizophrenia drugs Invega Sustenna/Xeplion and Invega Trinza /Trevicta as well as the launch of Invega Hafyera.
Oncology products grew 17.6%, bringing in $14.5 billion in 2021. Contributors to the growth were strong sales of Darzalex, driven by continued strong market growth, share gains in all regions and solid uptake of the subcutaneous formulation launched in 2020. Erleada and Imbruvica both had strong years despite competitive pressures from novel oral agents and COVID-19 related market dynamics including delays in new patient starts.
Pulmonary hypertension product sales of $3.5 billion increased 9.6% driven by positive performance of Opsumit and Uptravi. Cardiovascular/metabolism/other products sales fell 8.6% to $4.5 billion due to lower sales of Invokana/Invokamet and biosimlar competition for Procrit/Eprex.
J&J’s consumer health segment includes a broad range of products including over-the-counter (OTC) pharmaceuticals. In November 2021, J&J announced its intention to separate the consumer business, aiming to create a new, publicly traded company. The company intends to finalize the organizational design for its consumer group by the end of 2022 and plans to reveal a new name and headquarters location around the middle of 2023. The consumer health unit brought in $14.6 billion in 2021.
German independent research institute BioMed X entered several research projects with Janssen Research & Development. One aims to discover novel transport mechanisms in the human intestinal tract which could be utilized for oral delivery of diverse therapeutic modalities. Biologics such as monoclonal antibodies have transformed the treatment of immune-related diseases, but need to be delivered by injection, which may have higher barriers to use compared to oral delivery.
Another collaboration between the two firms set up two new research groups. One of the research groups is called PTA (Protective Tissue Factors in Autoimmune Diseases) and is led by Mojca Frank Bertoncelj, MD, PhD, who joined BioMed X from the University Hospital Zurich in Switzerland. Her research group will develop new approaches to combat chronic inflammatory diseases. The aim is to identify protective factors in the tissue microenvironment of patients with auto-inflammatory diseases.
The second research group, TMI (Translocation of Complex Macromolecules Across the Intestinal Epithelial Barrier), is led by Kyungbo Kim, PhD, and will look to discover novel transport mechanisms in the human intestinal tract that could be used for oral delivery of various macromolar therapeutic modalities. Dr. Kim is joining BioMed X from the University of Kentucky in Lexington.
Together with Remix Therapeutics, an RNA-focused company launched over a year ago developing its REMaster drug discovery platform, J&J entered a small molecule discovery and development collaboration. The partnership leverages Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing. While the collaboration details have not been disclosed, J&J will have exclusive rights to three specific targets with applications in immunology and oncology. The companies did not disclose targets or indications for the small molecules being developed.
Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, extended its existing R&D collaboration with J&J originally formed in July 2020. In June 2021, using its Q-Sphera technology, the company successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity. Midatech believes no other organization has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling.
Following the initial program (MTX213), the collaboration has been extended to include another large molecule to the research performed by Midatech for Janssen. The work will concentrate on maximizing drug loading and optimizing in vitro duration of release for this undisclosed Janssen experimental molecule using the Midatech’s Q-Sphera technology.
Novadiscovery, a health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, expanded its collaboration with J&J, initially entered in 2020. NOVA is now applying its collaborative clinical trial simulation platform, JINKO, to expand the existing lung cancer model to support Janssen market access and global medical affairs strategies. The companies are now working together to use the JINKO platform to add layers of biological complexity to the initial disease model and then run in silico trial simulations.
Most recently, J&J entered a discovery collaboration with Evotec SE. Evotec’s TargetAlloMod platforms will be evaluated to discover first-in-class novel mode of action therapeutic candidates. Evotec and Janssen will jointly conduct screens on the identified targets and collaborate with hit identification and lead optimization leveraging Evotec’s drug discovery and development platform.
twitter.com/JNJNews
www.jnj.com
Headcount: 141,700
Year Established: 1886
Pharma Revenues: $52,080 (+14%)
Net Income: $20,878 (+42%)
R&D: $14,714 (+21%)
TOP SELLING DRUGS
Drug | Indication | 2021 Sales | (+/-%) |
Stelara | psoriasis, Crohns’ disease, ulcerative colitis | $9,134 | 19% |
Darzalex | Multiple myeloma | $6,023 | 44% |
Imbruvica | oncology | $4,369 | 6% |
Invega | Sustenna schizophrenia | $4,022 | 10% |
Remicade | rheumatoid arthritis | $3,190 | -15% |
Xarelto | deep vein thrombosis pulmonary embolism | $2,438 | 4% |
COVID-19 Vaccine | COVID-19 | $2,385 | n/a |
Zytiga | prostate cancer | $2,297 | -7% |
Simponi | rheumatoid arthritis | $2,276 | 1% |
Tremfya | psoriasis, Crohns’ disease, ulcerative colitis | $2,127 | 58% |
Johnson & Johnson (J&J) is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. The pharmaceutical segment is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Sales across these therapeutic areas were $52 billion in 2021, a 14.3% growth over the previous year.
During the year, J&J received FDA approval for two new products: Rybrevant (amivantamab-vmjw), the first targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations, and Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis.
In addition to these newly launched products, J&J received approvals for additional indications, new formulations and combination therapies, and continued to advance key pipeline programs such as its BCMA-directed CAR-T cell therapy program and entry into gene therapy with a focus on retinal diseases.
Segment performance
Immunology product sales were $16.8 billion in 2021, an increase of 11.3%, driven by strong uptake of Stelara in Crohn’s disease and ulcerative colitis and strength in Tremfya in psoriasis. Growth was impacted somewhat by lower sales of Remicade due to biosimilar competition. Stelara, which brought in $5.9 billion, will also face biosimilar competition when it loses exclusivity in September 2023 in certain indications.Infectious disease product sales jumped 64% to $5.9 billion in 2021, driven largely by J&J’s COVID-19 vaccine. This was partially offset by lower sales of Prezista and Prezcobix/Rezolsta due to increased competition and loss of exclusivity of Prezista in certain countries outside the U.S.
Neuroscience products recorded sales of $7 billion, an increase of 7.1%. Paliperidone long-acting injectables growth was driven by sales of the schizophrenia drugs Invega Sustenna/Xeplion and Invega Trinza /Trevicta as well as the launch of Invega Hafyera.
Oncology products grew 17.6%, bringing in $14.5 billion in 2021. Contributors to the growth were strong sales of Darzalex, driven by continued strong market growth, share gains in all regions and solid uptake of the subcutaneous formulation launched in 2020. Erleada and Imbruvica both had strong years despite competitive pressures from novel oral agents and COVID-19 related market dynamics including delays in new patient starts.
Pulmonary hypertension product sales of $3.5 billion increased 9.6% driven by positive performance of Opsumit and Uptravi. Cardiovascular/metabolism/other products sales fell 8.6% to $4.5 billion due to lower sales of Invokana/Invokamet and biosimlar competition for Procrit/Eprex.
J&J’s consumer health segment includes a broad range of products including over-the-counter (OTC) pharmaceuticals. In November 2021, J&J announced its intention to separate the consumer business, aiming to create a new, publicly traded company. The company intends to finalize the organizational design for its consumer group by the end of 2022 and plans to reveal a new name and headquarters location around the middle of 2023. The consumer health unit brought in $14.6 billion in 2021.
R&D alliances
J&J entered several R&D alliances during the year. With TenNor Therapeutics (Suzhou) Ltd., a biopharmaceutical company dedicated to products for the treatment of diseases associated with bacterial infections and dysbioses, a research collaboration was established to leverage a multitargeting drug conjugation platform developed by TenNor to discover new therapies to treat nontuberculous mycobacteria (NTM) diseases.German independent research institute BioMed X entered several research projects with Janssen Research & Development. One aims to discover novel transport mechanisms in the human intestinal tract which could be utilized for oral delivery of diverse therapeutic modalities. Biologics such as monoclonal antibodies have transformed the treatment of immune-related diseases, but need to be delivered by injection, which may have higher barriers to use compared to oral delivery.
Another collaboration between the two firms set up two new research groups. One of the research groups is called PTA (Protective Tissue Factors in Autoimmune Diseases) and is led by Mojca Frank Bertoncelj, MD, PhD, who joined BioMed X from the University Hospital Zurich in Switzerland. Her research group will develop new approaches to combat chronic inflammatory diseases. The aim is to identify protective factors in the tissue microenvironment of patients with auto-inflammatory diseases.
The second research group, TMI (Translocation of Complex Macromolecules Across the Intestinal Epithelial Barrier), is led by Kyungbo Kim, PhD, and will look to discover novel transport mechanisms in the human intestinal tract that could be used for oral delivery of various macromolar therapeutic modalities. Dr. Kim is joining BioMed X from the University of Kentucky in Lexington.
Together with Remix Therapeutics, an RNA-focused company launched over a year ago developing its REMaster drug discovery platform, J&J entered a small molecule discovery and development collaboration. The partnership leverages Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing. While the collaboration details have not been disclosed, J&J will have exclusive rights to three specific targets with applications in immunology and oncology. The companies did not disclose targets or indications for the small molecules being developed.
Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, extended its existing R&D collaboration with J&J originally formed in July 2020. In June 2021, using its Q-Sphera technology, the company successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity. Midatech believes no other organization has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling.
Following the initial program (MTX213), the collaboration has been extended to include another large molecule to the research performed by Midatech for Janssen. The work will concentrate on maximizing drug loading and optimizing in vitro duration of release for this undisclosed Janssen experimental molecule using the Midatech’s Q-Sphera technology.
Novadiscovery, a health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, expanded its collaboration with J&J, initially entered in 2020. NOVA is now applying its collaborative clinical trial simulation platform, JINKO, to expand the existing lung cancer model to support Janssen market access and global medical affairs strategies. The companies are now working together to use the JINKO platform to add layers of biological complexity to the initial disease model and then run in silico trial simulations.
Most recently, J&J entered a discovery collaboration with Evotec SE. Evotec’s TargetAlloMod platforms will be evaluated to discover first-in-class novel mode of action therapeutic candidates. Evotec and Janssen will jointly conduct screens on the identified targets and collaborate with hit identification and lead optimization leveraging Evotec’s drug discovery and development platform.